Although it is possible that immunostimulatory therapy exacerbates the hyper‐inflammatory phase of sepsis, clinical trials of IFN‐γ, a potent immunostimulatory agent, and GM‐CSF in patients with various systemic inflammatory states did not elicit unbridled inflammatory reactions. This evidence concerns the gene CSF2 and Sepsis.